Theratechnologies Inc  

(Public, TSE:TH)   Watch this stock  
Find more results for tse:th
-0.09 (-2.12%)
Feb 17 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 4.05 - 4.29
52 week 1.26 - 4.29
Open 4.27
Vol / Avg. 526,435.00/129,324.00
Mkt cap 298.08M
P/E 672.61
Div/yield     -
EPS 0.01
Shares 71.44M
Beta 0.84
Inst. own     -
Feb 22, 2017
Q4 2016 Theratechnologies Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar

Key stats and ratios

Q4 (Nov '16) 2016
Net profit margin 1.67% 1.11%
Operating margin 20.18% 10.62%
EBITD margin - 16.31%
Return on average assets 1.34% 0.80%
Return on average equity 2.63% 1.75%
Employees 26 -
CDP Score - -


2015 Peel St 5th Floor
+1-514-3367800 (Phone)
+1-514-3319691 (Fax)

Website links


Theratechnologies Inc. is a Canada-based specialty pharmaceutical company. The Company addresses medical needs in metabolic disorders to promote healthy ageing among human immunodeficiency virus (HIV) patients. The Company's product, EGRIFTA (tesamorelin for injection), is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The Company's EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT).

Officers and directors

Dawn Svoronos Independent Chairman of the Board
Age: 62
Luc Tanguay President, Chief Executive Officer, Director
Age: 56
Philippe Dubuc Chief Financial Officer, Senior Vice President
Lyne Fortin Senior Vice President, Chief Commercial Officer
Christian Marsolais Ph.D. Senior Vice President - Scientific Affairs and Alliances
Age: 52
Marie-Noel Colussi Vice President - Finance
Age: 46
Jocelyn Lafond Vice President - Legal Affairs, Corporate Secretary
Age: 47
Pierre Perazzelli Vice President - Pharmaceutical Development
Age: 63
Gilles Cloutier Ph.D. Independent Director
Age: 70
Gerald A Lacoste Independent Director